CClinicalTrials.gg
CompletedNCT02142634Updated Jul 22, 2020

Budesonide for Induction of Remission in Incomplete Microscopic Colitis

A Phase 3 interventional study of Budesonide granules 9 mg and Placebo granules in Incomplete Microscopic Colitis, sponsored by Dr. Falk Pharma GmbH. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-07-22.

Sponsored by Dr. Falk Pharma GmbH · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to demonstrate the efficacy of budesonide for the treatment of active incomplete microscopic colitis.

02

Conditions studied

  • Incomplete Microscopic Colitis
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Histologically established diagnosis of incomplete microscopic colitis (MCi)
  • History of chronic non-bloody, watery diarrhoea
  • Clinically active disease

Exclusion criteria

Exclusion Criteria:

  • Other significant abnormalities in colonoscopy
  • Infectious cause of diarrhoea
  • Clinical suspicion of drug-induced diarrhoea
  • Prior and present MC
  • History of bowel resection
  • Radiation therapy of the abdominal or pelvic region
  • Positive antibody titres for celiac disease
  • Untreated active thyroid dysfunction
  • Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder reducing life expectancy
  • Abnormal hepatic function
  • Tuberculosis, hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, or infection if careful medical monitoring is not ensured
  • History of colorectal cancer
  • History of cancer (other than colorectal) in the last 5 years
  • Therapy with immunomodulators/budesonide or other steroids/antibiotics/anti-diarrhoeal drugs
  • Current or intended pregnancy or breast-feeding
  • Doubt about the patient's cooperation, e.g. because of addiction to alcohol or drugs
  • Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    A

    Budesonide granules 9 mg

    Drug: Budesonide granules 9 mg

  • Placebo comparator
    B

    Placebo granules

    Drug: Placebo granules

Interventions

  • DrugBudesonide granules 9 mg

    per day

  • DrugPlacebo granules

    per day

05

What researchers measure

Primary outcomes

  1. Rate of clinical remission

    Time frame: 8 weeks

Secondary outcomes

  1. Rate of clinical remission

    Time frame: 2 weeks

  2. Rate of clinical remission

    Time frame: 6 weeks

  3. Time to remission

    Time frame: 8 weeks

  4. Number of formed/soft/watery stools per week

    Time frame: 8 weeks

  5. Number of days with abdominal pain

    Time frame: 8 weeks

  6. Number of days with urgency

    Time frame: 8 weeks

  7. Rate of histological remission

    Time frame: 8 weeks

  8. Physician's global assessment at final visit

    Time frame: 8 weeks

  9. Quality of life

    Time frame: 8 weeks

06

Study locations

2 sites
  • Centre for Digestive Diseases
    Hamburg, 20249, Germany
  • University Hospital of Linköping, Dept. of Gastroenterology and Hepatology
    Linköping, 58185, Sweden
07

Registry details

Key details

Study ID
NCT02142634
Lead sponsor
Dr. Falk Pharma GmbH
Responsible party
Sponsor
First posted
May 20, 2014
Start date
May 2014
Primary completion
Feb 2020
Completion
Feb 2020
Last update
Jul 22, 2020

Study contacts

Andreas Münch, MD
principal investigator · University Hospital of Linköping, Dept. of Gastroenterology and Hepatology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion